# Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Canonical URL: https://biopharmsignal.com/news/JAGX/jaguar-health-research-in-ethnobotanical-medicine-helps-advance-crofelemer-development-for-genetically-defined-rare-congenital-gastrointestinal-disorders
Ticker: JAGX
Company: Jaguar Health
Source: Jaguar Health
Published: 2026-06-25 13:46 EST
Original Source URL: https://jaguarhealth.gcs-web.com
## Summary

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF)

## Article Body
Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a novel liquid formulation, is being developed as the potential first oral adjunctive therapy for Intestinal Failure (IF)
## Recent Company News
- 2026-06-30 13:00 EST — [Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)](https://biopharmsignal.com/news/JAGX/presentation-at-espghan-2026-describes-additional-groundbreaking-results-of-eval-34e0fbe8) — Source: Jaguar Health
- 2026-06-25 13:46 EST — [Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-conversion-of-series-o-convertible-preferred-stock-issued-as-recent-one-time-stock-dividend) — Source: Jaguar Health
- 2026-06-25 13:46 EST — [Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs](https://biopharmsignal.com/news/JAGX/jaguar-health-completes-submission-of-new-animal-drug-application-for-full-fda-approval-of-crofelemer-for-treatment-of-chemotherapy-induced-diarrhea-cid-in-dogs) — Source: Jaguar Health
- 2026-06-25 13:46 EST — [Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program](https://biopharmsignal.com/news/JAGX/jaguar-health-announces-plan-to-explore-strategic-alternatives-aligned-with-targeted-nda-filing-for-rare-disease-intestinal-failure-program) — Source: Jaguar Health
- 2026-06-25 13:46 EST — [Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention](https://biopharmsignal.com/news/JAGX/magdalena-biosciences-a-joint-venture-between-jaguar-health-and-filament-health-announces-positive-results-of-preclinical-study-of-coca-for-weight-gain-prevention) — Source: Jaguar Health
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)